参考文献
(在框内滑动手指即可浏览)
[1] Lawrence W Jr, Lopez MJ. Radical surgery for cancer: a historical perspective [J]. Surg Oncol Clin N Am, 2005, 14(3): 441-446, v.
[2] Halsted WS. The Results of Radical Operations for the Cure of Carcinoma of the Breast [J]. Ann Surg, 1907, 46(1): 1-19.
[3] Patey DH, Dyson WH. The prognosis of carcinoma of the breast in relation to the type of operation performed [J]. Br J Cancer, 1948, 2(1): 7-13.
[4] Auchincloss H. Significance of location and number of axillary metastases in carcinoma of the breast [J]. Ann Surg, 1963, 158(1): 37-46.
[5] Fisher B, Montague E, Redmond C,et al. Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome [J]. Cancer, 1980, 46(1): 1-13.
[6] Fisher B, Wolmark N, Redmond C, et al. Findings from NSABP Protocol No. B-04: comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-central breast cancers [J]. Cancer, 1981, 48(8): 1863-1872.
[7] Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer [J]. N Engl J Med, 1985, 312(11): 665-673.
[8] Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer [J]. N Engl J Med, 2002, 347(16): 1233-1241.
[9] Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial [J]. Lancet Oncol, 2010, 11(10): 927-933.
[10] Latosinsky S, Dabbs K, Moffat F, et al. Canadian Association of General Surgeons and American College of Surgeons Evidence-Based Reviews in Surgery. 27. Quality-of-life outcomes with sentinel node biopsy versus standard axillary treatment in patients with operable breast cancer. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial [J]. Can J Surg, 2008, 51(6): 483-485.
[11] Ye JM, Guo BL, Liu Q, et al. Clinical practice guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021 [J]. Chin Med J (Engl), 2021, 134(8): 886-894.
[12] Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial [J]. J Natl Cancer Inst, 2006, 98(9): 599-609.
[13] Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer [J]. N Engl J Med, 2003, 349(6): 546-553.
[14] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast cancer. Version 8. 2021 [EB/OL]. (2021-9-13) [2021-11-17]. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
[15] Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update [J]. J Clin Oncol, 2017, 35(5): 561-564.
[16] Sun X, Li H, Liu YB, et al. Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences [J]. Oncol Lett, 2015, 10(3): 1932-1938.
[17] Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study [J]. J Clin Oncol, 2009, 27(5): 726-732.
[18] Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients [J]. Ann Surg, 2009, 250(4): 558-566.
[19] Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study [J]. Lancet Oncol, 2013, 14(7): 609-618.
[20] Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial [J]. JAMA, 2013, 310(14): 1455-1461.
[21] Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study [J]. J Clin Oncol, 2015, 33(3): 258-264.
[22] DeSnyder SM, Mittendorf EA, Le-Petross C, et al. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer [J]. Clin Breast Cancer, 2018, 18(1): e73-e77.
[23] 中华医学会外科学分会乳腺外科学组. 早期乳腺癌染料法前哨淋巴结活检专家共识及技术操作指南(2018版) [J]. 中国实用外科杂志, 2018, 38(8): 855-858.
[24] OʼReilly EA, Prichard RS, Al Azawi D, et al. The Value of Isosulfan Blue Dye in Addition to Isotope Scanning in the Identification of the Sentinel Lymph Node in Breast Cancer Patients With a Positive Lymphoscintigraphy: A Randomized Controlled Trial (ISRCTN98849733) [J]. Ann Surg, 2015, 262(2): 243-248.
[25] Hung WK, Chan CM, Ying M, et al. Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer [J]. Br J Surg, 2005, 92(12): 1494-1497.
[26] Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye [J]. Ann Surg, 2001, 233(1): 51-59.
[27] Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis [J]. Cancer, 2006, 106(1): 4-16.
[28] Niebling MG, Pleijhuis RG, Bastiaannet E, et al. A systematic review and meta-analyses of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping [J]. Eur J Surg Oncol, 2016, 42(4): 466-473.
[29] Peek MC, Charalampoudis P, Anninga B, et al Blue dye for identification of sentinel nodes in breast cancer and malignant melanoma: a systematic review and meta-analysis [J]. Future Oncol, 2017, 13(5): 455-467.
[30] Qin X, Yang M, Zheng X. Comparative study of indocyanine green combined with blue dye with methylene blue only and carbon nanoparticles only for sentinel lymph node biopsy in breast cancer [J]. Ann surg Treat Res, 2019, 97(1): 1-6.
[31] Goonawardena J, Yong C, Law M. Use of indocyanine green fluorescence compared to radioisotope for sentinel lymph node biopsy in early-stage breast cancer: systematic review and meta-analysis [J]. Am J Surg, 2020, 220(3): 665-676.
[32] Wang C, Tong F, Cao Y, et al. Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer [J]. Breast Cancer Res Treat, 2021, 188(2): 361-368.
[33] Wu X, Lin Q, Chen G, et al. Sentinel lymph node detection using carbon nanoparticles in patients with early breast cancer [J]. PLoS One, 2015, 10(8): e0135714.
[34] 王敏, 姚峰. 应用纳米炭混悬液行乳腺癌前哨淋巴结活检的临床研究 [J]. 中华实用诊断与治疗杂志, 2018, 32(4): 358-361.
[35] Giuliano AE, Jones RC, Brennan M,et al. Sentinel lymphadenectomy in breast cancer [J]. J Clin Oncol, 1997, 15(6): 2345-2350.
[36] Jung SY, Han JH, Park SJ, et al. The sentinel lymph node biopsy using indocyanine green fluorescence plus radioisotope method compared with the radioisotope-only method for breast cancer patients after neoadjuvant chemotherapy: A prospective, randomized, open-label, single-center phase 2 trial [J]. Ann Surg Oncol, 2019, 26(8): 2409-2416.
[37] Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review [J]. Lancet Oncol, 2014, 15(8): e351-362.
[38] Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe [J]. Surg Oncol, 1993, 2(6): 335-339; discussion 340.
[39] 中华医学会肿瘤学分会乳腺癌学组. 乳腺癌荧光示踪前哨淋巴结活组织检查操作指南 [J]. 中华乳腺病杂志(电子版), 2017, 11(4): 193-197.
[40] Ahmed M, Purushotham AD, Horgan K, et al. Meta-analysis of superficial versus deep injection of radioactive tracer and blue dye for lymphatic mapping and detection of sentinel lymph nodes in breast cancer [J]. Br J Surg, 2015, 102(3): 169-181.
[41] Kern KA. Concordance and validation study of sentinel lymph node biopsy for breast cancer using subareolar injection of blue dye and technetium 99m sulfur colloid [J]. J Am Coll Surg, 2002, 195(4): 467-475.
[42] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版) [J]. 中国癌症杂志, 2019, 29(8): 609-679.
[43] Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 [J]. Ann Oncol, 2019, 30(10): 1541-1557.
[44] Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial [J]. Lancet Oncol, 2007, 8(10): 881-888.
[45] Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study [J]. Ann Surg, 2010, 251(4): 595-600.
[46] Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J]. J Clin Oncol, 2005, 23(12): 2694-2702.
[47] Classe JM, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study [J]. Breast Cancer Res Treat, 2019, 173(2): 343-352.
[48] Abe M, Yamada T, Nakano A. Prospective Comparison of Intraoperative Touch Imprint Cytology and Frozen Section Histology on Axillary Sentinel Lymph Nodes in Early Breast Cancer Patients [J]. Acta Cytol, 2020, 64(5): 492-497.
[49] Vohra LM, Gulzar R, Saleem O. Intra operative frozen examination of sentinel lymph node in breast cancer [J]. J Ayub Med Coll Abbottabad, 2015, 27(1): 40-44.
[50] Chan YH, Hung WK, Mak KL, et al. Intra-operative assessment of axillary sentinel lymph nodes by frozen section-an observational study of 260 procedures [J]. Asian J Surg, 2011, 34(2): 81-85.
[51] Mori M, Tada K, Ikenaga M, et al. Frozen section is superior to imprint cytology for the intra-operative assessment of sentinel lymph node metastasis in stage I breast cancer patients [J]. World J Surg Oncol, 2006, 4: 26.
[52] 王朝斌, 王殊, 彭媛,等. 后ACSOGZ0011时代术中冰冻病理评估乳腺癌前哨淋巴结转移的价值 [J]. 中国妇产科临床杂志, 2017, 18(3): 233-235.
[53] FitzgibbonsPL,Connolly JL,Bose S,et al.Protocol for the Examination of Resection Specimens From Patients With Invasive Carcinoma of the Breast. v4.4.0.0[EB/OL]. Winnetka: College of American Pathologists.(202-02)[2021-11-03]https://documents.cap.org/protocols/cp-breast-invasive-resection-20-4400.pdf.
[54] Delgado-Bocanegra RE, Millen EC, Nascimento CMD, et al. Intraoperative imprint cytology versus histological diagnosis for the detection of sentinel lymph nodes in breast cancer treated with neoadjuvant chemotherapy [J]. Clinics (Sao Paulo), 2018, 73: e363.
[55] Nährig J, Richter T, Kowolik J, et al. Comparison of different histopathological methods for the examination of sentinel lymph nodes in breast cancer [J]. Anticancer Res, 2000, 20(3b): 2209-2212.
[56] Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial [J]. Ann Surg, 2016, 264(3): 413-420.
[57] Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial [J]. Lancet Oncol, 2018, 19(10): 1385-1393.
[58] Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial [J]. Lancet Oncol, 2013, 14(4): 297-305.
[59] Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial [J]. Lancet Oncol, 2014, 15(12): 1303-1310.
[60] Huang TW, Kuo KN, Chen KH, et al. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system [J]. Int J Surg, 2016, 34: 73-80.
[61] Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis [J]. Breast Cancer Res Treat, 2011, 129(3): 675-689.
[62] Sun X, Wang XE, Zhang ZP, et al. Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial [J]. Breast Cancer Res Treat, 2020, 180(2): 423-428.
[63] Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic Mapping and Sentinel Lymphadenectomy for Breast-Cancer [J]. Ann Surg, 1994, 220(3): 391-401.
[64] 王永胜, 左文述, 刘娟娟, 等. 乳腺癌前哨淋巴结活检替代腋窝清扫术前瞻性非随机对照临床研究 [J]. 外科理论与实践, 2006,11 (2): 104-107.
[65] Boughey JC, Ballman KV, Hunt KK, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance) [J]. J Clin Oncol, 2015, 33(30): 3386-3393.
[66] Lucci A Jr, Kelemen PR, Miller C, et al. National practice patterns of sentinel lymph node dissection for breast carcinoma [J]. J Am Coll Surg, 2001, 192(4): 453-458.
[67] Li J, Chen X, Qi M, et al. Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: A systematic review and meta-analysis [J]. PLoS One, 2018, 13(9): e0204364.
[68] Zhang L, Huang Y, Yang C, et al. Application of a carbon nanoparticle suspension for sentinel lymph node mapping in patients with early breast cancer: a retrospective cohort study [J]. World J Surg Oncol, 2018, 16(1): 112.
[69] Paulinelli RR, Freitas-Junior R, Rahal RM, et al. A prospective randomized trial comparing patent blue and methylene blue for the detection of the sentinel lymph node in breast cancer patients [J]. Rev Assoc Med Bras (1992), 2017, 63(2): 118-123.
[70] 曹迎明, 王殊, 郭嘉嘉, 等. 吲哚菁绿联合美蓝在乳腺癌前哨淋巴结活检术中的应用 [J]. 中华普通外科杂志, 2014, 29(2): 119-122.
[71] 任敏, 王本忠, 陈樱, 等. 吲哚菁绿-纳米碳联合示踪在乳腺癌前哨淋巴结活检中的应用 [J]. 中华内分泌外科杂志, 2015, 9(2): 97-100.
[72] Amin MB, EdgeES, Greene FL, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York, NY: Springer, 2017.
[73] 王永胜, 欧阳涛, 王启堂, 等. 中国前哨淋巴结活检多中心协作研究CBCSG-001最新资料报告 [J]. 中华乳腺病杂志(电子版), 2009, 3(3): 265-272.
[74] Wong J, Yong WS, Thike AA, et al. False negative rate for intraoperative sentinel lymph node frozen section in patients with breast cancer: a retrospective analysis of patients in a single Asian institution [J]. J Clin Pathol, 2015, 68(7): 536-540.
[75] Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial [J]. JAMA, 2017, 318(10): 918-926.
[76] Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2019, 30(10): 1674.
[77] Shirzadi A, Mahmoodzadeh H, Qorbani M. Assessment of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer in two subgroups: Initially node negative and node positive converted to node negative - A systemic review and meta-analysis [J]. J Res Med Sci,2019, 24: 18.
[78] Zetterlund LH, Frisell J, Zouzos A, et al. Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer [J]. Breast Cancer Res Treat, 2017, 163(1): 103-110.
[79] Pilewskie M, Morrow M. Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review [J]. JAMA Oncol, 2017, 3(4): 549-555.
[80] 国家药典委员会. 中华人民共和国药典. 2015版[M]. 北京: 中国医药科技出版社, 2015.
[81] James TA, Coffman AR, Chagpar AB, et al. Troubleshooting sentinel lymph node biopsy in breast cancer surgery [J]. Ann Surg Oncol, 2016, 23(11): 3459-3466.
[82] Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node biopsy in pregnant women with breast cancer [J]. Ann Surg Oncol, 2014, 21(8): 2506-2511.
[83] Ng BK, Cameron AJ, Liang R, et al. Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review [J]. Can J Anaesth, 2008, 55(1): 36-41.
[84] Van Diest PJ, Torrenga H, Borgstein PJ, et al. Reliability of intraoperative frozen section and imprint cytological investigation of sentinel lymph nodes in breast cancer [J]. Histopathology, 1999, 35(1): 14-18.
[85] Lombardi A, Nigri G, Maggi S, et al. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials [J]. Surgeon, 2018,16(4):232-236.